2021

InteRNA Technologies Announces U.S. FDA Clearance of IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3

InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board

InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board

GBR Connect Series - Interview with Roel Schaapveld, InteRNA Technologies - US Pharma & Biopharma

InteRNA Technologies Publishes Preclinical Data from Investigational microRNA INT-1B3 Program in Molecular Therapy – Nucleic Acids and Oncotarget

InteRNA and the renewed interest in RNA therapeutics in the March 2021 edition of MedNous

InteRNA Technologies Awarded € 2.7M Clinical Innovation Credit from Dutch Government

InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors

InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M

InteRNA in de Kerstbijlage van het Algemeen Dagblad d.d. 17 december 2020: Nieuwe vorm van immunotherapie helpt bij de bestrijding van kanker.

Archives

2020

CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial

Recently a short movie about InteRNA and it’s lead compound for the treatment of cancer was broadcasted in the RTL4/RTLZ program “Zo kan het ook”. Watch the video with the latest news here

InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors

InteRNA steunt de campagne Innovaties in Oncologie van @Mediaplanet. Leer meer over verschillende innovaties in oncologie zoals immuuntherapieën van thought leaders, zoals Ton Schumacher online of in de New Scientist (24 maart 2020)

2019

InteRNA presents data on potential of lead oncology development candidate INT-1B3 in immuno-oncology at the SelectBIO Immuno-Oncology Europe 2019 meeting

InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting

InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy

InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board

2018

InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting

InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting

InteRNA to Present Preclinical Proof-of-Concept Data on Lead microRNA Candidate INT-1B3 at 2018 AACR Annual Meeting

New Journal of Neuroscience paper shows that our functional screening platform for miRNA drug candidates works also nicely outside Oncology

2017

New Cancer Research paper on the Mode of Action of one of our proprietary miRNA drug candidates for the treatment of epithelial cancers by UMC radboud icw InteRNA Technologies under our STW grant program

2016

InteRNA builds Management Team for next stage of development

2015

InteRNA Technologies secures final extension Series A financing and strengthens its Supervisory Board

2014

InteRNA Technologies, UCB and University of Bonn to collaborate on the role of microRNAs in neurodegenerative disease

2013

MiRacle Consortium led by InteRNA Technologies and VU University Medical Center

InteRNA Technologies partner in €11.5 Million EU Framework Program 7

InteRNA Technologies also receives notice of allowance for its melanoma lead compound miRNA-3157 in Australia

SomantiX B.V. and InteRNA Technologies B.V. obtain a MIT R&D collaboration grant

InteRNA's R&D collaboration partner UMC St. Radboud receives grant from Stichting voor de Technische Wetenschappen

2012

InteRNA Technologies receives notice of allowance for miRNA sequences of its lead pre-clinical product

InteRNA Technologies B.V. announces full consolidation of its subsidiary InteRNA Genomics B.V. as of July 1, 2012

2011

InteRNA Technologies announces establishment of Supervisory Board

Silence Therapeutics and InteRNA Technologies sign collaboration to develop novel microRNA therapeutics

InteRNA Technologies Strengthens its R&D Team Nijmegen/Utrecht (the Netherlands)

2010

InteRNA Technologies Awarded EUR 1.3 million Innovation Credit from Dutch Government Utrecht (the Netherlands)

InteRNA Technologies announces establishment of Scientific Advisory Board Utrecht (the Netherlands)

2009

InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways

New small and medium enterprises join TIPharma by signing two new projects

InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer

2008

InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery

InteRNA Technologies Joins European SIROCCO Consortium to Study RNA Silencing

InteRNA Technologies and VU University Medical Center to Develop microRNA-based Diagnostics and Therapeutics for Cancer